$2.76 Billion is the total value of Rock Springs Capital Management LP's 135 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 23.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WCG | Buy | WELLCARE HEALTH PLANS INC | $91,365,000 | +5.8% | 320,500 | +0.2% | 3.30% | -0.7% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $86,372,000 | +16.1% | 1,023,000 | +21.1% | 3.12% | +9.0% |
| EHC | Buy | ENCOMPASS HEALTH CORP | $51,005,000 | +9.2% | 805,000 | +0.6% | 1.84% | +2.4% |
| BMY | New | BRISTOL MYERS SQUIBB CO | $47,618,000 | – | 1,050,000 | +100.0% | 1.72% | – |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $41,548,000 | +354.6% | 1,880,000 | +180.6% | 1.50% | +327.0% |
| PEN | Buy | PENUMBRA INC | $38,240,000 | +15.6% | 239,000 | +6.2% | 1.38% | +8.5% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $36,872,000 | +36.0% | 1,055,000 | +14.1% | 1.33% | +27.7% |
| RDUS | Buy | RADIUS HEALTH INC | $30,450,000 | +30.0% | 1,250,000 | +6.4% | 1.10% | +22.0% |
| MDCO | Buy | MEDICINES CO | $29,176,000 | +43.1% | 800,000 | +9.7% | 1.06% | +34.4% |
| PODD | New | INSULET CORP | $29,188,000 | – | 244,500 | +100.0% | 1.06% | – |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $29,006,000 | +31.8% | 307,500 | +11.8% | 1.05% | +23.6% |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $28,980,000 | – | 600,000 | +100.0% | 1.05% | – |
| CI | Buy | CIGNA CORP NEW | $28,721,000 | +98.4% | 182,300 | +102.6% | 1.04% | +86.2% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $27,347,000 | -9.9% | 1,008,000 | +15.2% | 0.99% | -15.5% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $26,926,000 | -15.8% | 256,900 | +0.6% | 0.97% | -21.0% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $23,778,000 | +9.0% | 327,700 | +40.3% | 0.86% | +2.3% |
| EPZM | Buy | EPIZYME INC | $23,219,000 | +6.9% | 1,850,100 | +5.5% | 0.84% | +0.2% |
| INSM | Buy | INSMED INC | $22,784,000 | -7.8% | 890,000 | +4.7% | 0.82% | -13.5% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $20,858,000 | +58.1% | 202,500 | +12.5% | 0.76% | +48.3% |
| ZLAB | Buy | ZAI LAB LTDadr | $19,179,000 | +57.2% | 550,000 | +33.0% | 0.69% | +47.7% |
| RTRX | Buy | RETROPHIN INC | $19,086,000 | +1.6% | 950,000 | +14.5% | 0.69% | -4.7% |
| PHAS | Buy | PHASEBIO PHARMACEUTICALS INC | $18,673,000 | +72.2% | 1,423,256 | +24.8% | 0.68% | +61.7% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $18,388,000 | -13.6% | 1,562,300 | +0.1% | 0.66% | -19.0% |
| XENT | Buy | INTERSECT ENT INC | $17,980,000 | +20.3% | 790,000 | +69.9% | 0.65% | +12.8% |
| WST | Buy | WEST PHARMACEUTICAL SVSC INC | $17,208,000 | +24.9% | 137,500 | +10.0% | 0.62% | +17.3% |
| GH | Buy | GUARDANT HEALTH INC | $16,403,000 | +18.8% | 190,000 | +5.6% | 0.59% | +11.5% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $15,042,000 | +12.4% | 343,500 | +32.1% | 0.54% | +5.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $13,939,000 | +7.5% | 265,000 | +8.2% | 0.50% | +0.8% |
| NVRO | Buy | NEVRO CORP | $12,674,000 | +484.3% | 195,500 | +463.4% | 0.46% | +446.4% |
| IMMU | Buy | IMMUNOMEDICS INC | $12,414,000 | -19.2% | 895,000 | +11.9% | 0.45% | -24.3% |
| ANAB | Buy | ANAPTYSBIO INC | $12,328,000 | -0.7% | 218,500 | +28.5% | 0.45% | -6.9% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $12,205,000 | +1.8% | 142,500 | +5.6% | 0.44% | -4.3% |
| ABBV | New | ABBVIE INC | $10,908,000 | – | 150,000 | +100.0% | 0.40% | – |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $8,505,000 | +7.3% | 170,500 | +45.1% | 0.31% | +0.7% |
| FIXX | Buy | HOMOLOGY MEDICINES INC | $8,317,000 | -18.9% | 425,000 | +14.9% | 0.30% | -24.0% |
| KRTX | New | KARUNA THERAPEUTICS INC | $8,278,000 | – | 413,500 | +100.0% | 0.30% | – |
| ACHN | Buy | ACHILLION PHARMACEUTICALS IN | $7,906,000 | -1.1% | 2,950,000 | +9.3% | 0.29% | -7.1% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $7,554,000 | -14.8% | 560,000 | +24.4% | 0.27% | -20.2% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $6,792,000 | -61.8% | 534,400 | +16.7% | 0.25% | -64.1% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $6,444,000 | -32.1% | 900,000 | +25.9% | 0.23% | -36.3% |
| BLUE | Buy | BLUEBIRD BIO INC | $5,978,000 | -15.6% | 47,000 | +4.4% | 0.22% | -20.9% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $5,170,000 | -12.9% | 235,000 | +8.5% | 0.19% | -18.3% |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $5,140,000 | – | 351,100 | +100.0% | 0.19% | – |
| GMDA | New | GAMIDA CELL LTD | $5,080,000 | – | 1,000,000 | +100.0% | 0.18% | – |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $4,441,000 | -56.4% | 2,028,000 | +19.3% | 0.16% | -59.0% |
| AKRO | New | AKERO THERAPEUTICS INC | $4,309,000 | – | 225,000 | +100.0% | 0.16% | – |
| MYOV | Buy | MYOVANT SCIENCES LTD | $4,073,000 | -50.9% | 450,000 | +29.5% | 0.15% | -54.1% |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $3,979,000 | – | 50,000 | +100.0% | 0.14% | – |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $3,931,000 | +120.5% | 425,000 | +53.3% | 0.14% | +105.8% |
| ADAP | Buy | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $3,518,000 | +2.3% | 875,000 | +9.4% | 0.13% | -4.5% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $3,172,000 | -53.1% | 526,100 | +4.2% | 0.12% | -55.9% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $2,594,000 | -6.6% | 650,000 | +71.1% | 0.09% | -12.1% |
| NVAX | New | NOVAVAX INC | $952,000 | – | 162,500 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.